Zymeworks (ZYME) News Today $13.37 -0.40 (-2.90%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Zymeworks Inc. (NYSE:ZYME) Stock Holdings Trimmed by Wellington Management Group LLPWellington Management Group LLP lessened its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 27.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 243,189 shares of the company's stock aDecember 18 at 3:45 AM | marketbeat.comZymeworks (NYSE:ZYME) Upgraded to Overweight at JPMorgan Chase & Co.December 18 at 2:21 AM | americanbankingnews.comJP Morgan Upgrades Zymeworks (ZYME)December 17 at 5:38 PM | msn.comZymeworks (NYSE:ZYME) Shares Gap Up - Here's WhyZymeworks (NYSE:ZYME) Shares Gap Up - Here's What HappenedDecember 16 at 11:43 AM | marketbeat.comZymeworks (NYSE:ZYME) Upgraded at JPMorgan Chase & Co.JPMorgan Chase & Co. raised Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective for the company in a report on Monday.December 16 at 7:09 AM | marketbeat.comZymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth PlansDecember 13, 2024 | finance.yahoo.comZymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory DiseasesDecember 12, 2024 | markets.businessinsider.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. lessened its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 74.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,583 shares of the company's stock after selDecember 12, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives $19.00 Consensus Target Price from AnalystsDecember 8, 2024 | americanbankingnews.comJacobs Levy Equity Management Inc. Has $6.56 Million Stake in Zymeworks Inc. (NYSE:ZYME)Jacobs Levy Equity Management Inc. reduced its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 19.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 522,640 shares of the company's stock after selliDecember 6, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stake in Zymeworks Inc. (NYSE:ZYME)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Zymeworks Inc. (NYSE:ZYME - Free Report) by 19.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,524,084 shDecember 6, 2024 | marketbeat.comRedmile Group LLC Sells 109,126 Shares of Zymeworks Inc. (NYSE:ZYME)Redmile Group LLC decreased its stake in Zymeworks Inc. (NYSE:ZYME - Free Report) by 2.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,101,911 shares of the company's stock after selDecember 5, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Zymeworks Inc. (NYSE:ZYME - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has iDecember 3, 2024 | marketbeat.comVestal Point Capital LP Boosts Stake in Zymeworks Inc. (NYSE:ZYME)Vestal Point Capital LP increased its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 39.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 615,000 shares of the company's stock after buying an aNovember 29, 2024 | marketbeat.comZymeworks Gains Buy Rating Amid FDA Approval and Market Expansion Potential for ZanidatamabNovember 25, 2024 | markets.businessinsider.comBloom Burton Forecasts Zymeworks FY2024 EarningsZymeworks Inc. (NYSE:ZYME - Free Report) - Investment analysts at Bloom Burton issued their FY2024 earnings per share (EPS) estimates for shares of Zymeworks in a note issued to investors on Thursday, November 21st. Bloom Burton analyst D. Martin expects that the company will post earnings of ($1November 25, 2024 | marketbeat.comIn-Depth Examination Of 9 Analyst Recommendations For ZymeworksNovember 22, 2024 | benzinga.comZymeworks' (ZYME) Neutral Rating Reiterated at HC WainwrightHC Wainwright restated a "neutral" rating and set a $12.00 price target on shares of Zymeworks in a research note on Friday.November 22, 2024 | marketbeat.comZymeworks Inc.: Zymeworks Announces Participation in Upcoming Investor ConferencesNovember 22, 2024 | finanznachrichten.deZymeworks Announces Participation in Upcoming Investor ConferencesNovember 21, 2024 | globenewswire.comFDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)November 21, 2024 | globenewswire.comFY2024 EPS Estimates for Zymeworks Raised by Leerink PartnrsZymeworks Inc. (NYSE:ZYME - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Zymeworks in a research note issued to investors on Thursday, November 7th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings of ($0.3November 11, 2024 | marketbeat.comLeerink Partners Upgrades Zymeworks (ZYME)November 10, 2024 | msn.comQ4 Earnings Forecast for Zymeworks Issued By Leerink PartnrsZymeworks Inc. (NYSE:ZYME - Free Report) - Equities research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for Zymeworks in a report issued on Thursday, November 7th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn $0.70 per shareNovember 8, 2024 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from AnalystsZymeworks Inc. (NYSE:ZYME - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendNovember 8, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Upgraded at Leerink PartnrsLeerink Partnrs raised shares of Zymeworks from a "hold" rating to a "strong-buy" rating in a research report on Thursday.November 8, 2024 | marketbeat.comZymeworks upgraded to Outperform from Market Perform at LeerinkNovember 7, 2024 | markets.businessinsider.comZymeworks (NYSE:ZYME) Upgraded at Leerink PartnersLeerink Partners upgraded shares of Zymeworks from a "market perform" rating to an "outperform" rating and upped their price objective for the stock from $10.00 to $25.00 in a report on Thursday.November 7, 2024 | marketbeat.comZymeworks says first patient dosed in Phase 1 trial of ZW191November 6, 2024 | markets.businessinsider.comZymeworks doses first subject in Phase I trial of ZW191 for solid tumoursNovember 6, 2024 | msn.comZymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid TumorsNovember 5, 2024 | tmcnet.comZymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid TumorsNovember 5, 2024 | globenewswire.comZymeworks price target raised to $18 from $16 at CitiNovember 4, 2024 | markets.businessinsider.comZymeworks (NYSE:ZYME) Hits New 52-Week High on Analyst UpgradeZymeworks (NYSE:ZYME) Reaches New 12-Month High on Analyst UpgradeNovember 4, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Given New $18.00 Price Target at CitigroupCitigroup lifted their price objective on shares of Zymeworks from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Monday.November 4, 2024 | marketbeat.comZymeworks: Turning The Tide With 2 Key Milestones For ZanidatamabNovember 4, 2024 | seekingalpha.comWells Fargo Downgrades Zymeworks (ZYME)November 2, 2024 | msn.comZymeworks Third Quarter 2024 Earnings: Revenues DisappointNovember 2, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Regeneron (REGN)November 2, 2024 | markets.businessinsider.comZymeworks (NYSE:ZYME) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPSZymeworks (NYSE:ZYME - Get Free Report) released its earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The firm had revenue of $16.00 million during the quarter, compared to analysts' expectations of $17.90 million. During the same period in the prior year, the company earned ($0.41) earnings per share. The company's quarterly revenue was down 3.1% on a year-over-year basis.November 1, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Shares Gap Down - Should You Sell?Zymeworks (NYSE:ZYME) Shares Gap Down - Here's What HappenedNovember 1, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Earns Neutral Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating and set a $12.00 price objective on shares of Zymeworks in a research report on Friday.November 1, 2024 | marketbeat.comZymeworks (NYSE:ZYME) Rating Lowered to "Equal Weight" at Wells Fargo & CompanyWells Fargo & Company cut Zymeworks from an "overweight" rating to an "equal weight" rating and set a $12.00 price objective for the company. in a report on Friday.November 1, 2024 | marketbeat.comZymeworks Inc (ZYME) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesNovember 1, 2024 | finance.yahoo.comZymeworks Inc. 2024 Q3 - Results - Earnings Call PresentationOctober 31, 2024 | seekingalpha.comAssenagon Asset Management S.A. Purchases Shares of 331,144 Zymeworks Inc. (NYSE:ZYME)Assenagon Asset Management S.A. purchased a new stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 331,144 shares of the company's stock, valued at approximately $4,156,000. Assenagon Asset ManagOctober 30, 2024 | marketbeat.comZymeworks to Spotlight Innovations at Investor ConferencesOctober 29, 2024 | msn.comZymeworks price target raised to $28 from $21 at StifelOctober 29, 2024 | markets.businessinsider.comZymeworks Announces Participation in Upcoming Investor ConferencesOctober 29, 2024 | globenewswire.comZymeworks (NYSE:ZYME) Price Target Raised to $28.00 at Stifel NicolausStifel Nicolaus lifted their price objective on Zymeworks from $21.00 to $28.00 and gave the stock a "buy" rating in a report on Monday.October 28, 2024 | marketbeat.com Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address A conspiracy Trump won’t unseal (Ad)New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous. This is the untold, true story of God’s Investment. ZYME Media Mentions By Week ZYME Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZYME News Sentiment▼1.290.71▲Average Medical News Sentiment ZYME News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZYME Articles This Week▼94▲ZYME Articles Average Week Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OGN News PTCT News VRNA News RYTM News MLTX News JANX News EWTX News XENE News MRUS News ACAD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ZYME) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
